1. software
  2. rnatarget technology

SOPHiA DDM -RNAtarget Technology

SHARE

Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions. Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable fusions. RNA sequencing fusion detection has become an integral tool of cancer research, as it allows clinical researchers to identify genetic abnormalities that trigger oncogenesis and progression.

Most popular related searches
  • High-performance novel fusion detection
  • Optimized for small FFPE samples using 10ng of RNA or tNA minimum input
  • Customizable gene content and full Set Up Program
  • Streamlined 1.5-day end-to-end workflow, automation-friendly
  • Detect and interpret novel fusions, SNVs, and Indels in major lung cancer biomarkers (45 relevant genes)
  • Streamlined visualization , filtering and reporting with the SOPHiA DDM™ Platform

Unleash the capabilities of RNA Sequencing and expand your cancer research insights using SOPHiA GENETICS’s end-to-end applications for small tumor samples

Our comprehensive portfolio offers ready-to-use and customizable solutions based on RNAtarget Technology features and performances

SOPHiA DDM™? RNAtarget Oncology Solution
SOPHiA DDM™? RNAtarget Oncology Solution is a comprehensive application that covers 45 genes relevant for solid tumors, with a focus on lung cancer.

SOPHiA DDM™? Dx RNAtarget Oncology Solution
SOPHiA DDM™? Dx RNAtarget Oncology Solution is also available as a CE-IVD product, enabling novel fusion detection in small samples to improve lung cancer management. Read More

SOPHiA GENETICS™ Community Panels
SOPHiA GENETICS™ Community Panels are targeted panels developed and tested by genomic experts of their fields to minimize set-up challenges and accelerate your workflow.

Custom Applications
SOPHiA GENETICS™ Custom applications are panels specifically designed at your request to analyze genes relevant to your laboratory.

SOPHiA DDM™ RNAtarget Oncology Solution covers 45 genes associated with solid tumors, with a focus on lung cancer biomarkers. Our technology offers novel (partner-agnostic) fusion detection combined with the ability to detect SNVs/Indels and unlock the capacity to assess expression changes. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions. For specific needs, the gene content can be fully customized.

  • Minimal RNA/tNA input amount required
  • Comprehensive variants detection, visualization and filtering
  • Direct access to the latest scientific evidence via OncoPortal™ Plus
  • Intuitive and fully automated reporting

Parameters: SOPHiA DDM™ RNAtarget Technology

  • Sample Type: FFPE, fresh frozen tissue
  • Input Type: RNA or tNA
  • Input Amount: 10-200 ng, 50 ng recommended
  • Sequencer Compatibility:
    • Illumina MiSeq®
    • Illumina NextSeg® 550
  • Library Preparation Time: 1.5 days
  • Analysis Time From FASTQ File: 8h/16 sample batch
  • Detected Variants:
    • Novel fusions
    • SNVs/Indels
    • Expression changes